Sanofi and Blackstone enter multimillion-euro partnership on bone marrow cancer drug

Blackstone is committing itself to help Sanofi’s drug, Sarclisa, reach the market in a subcutaneous formulation. A phase III study is slated to begin in a few months.


Blackstone Life Sciences, which is part of the Blackstone group, has entered a collaboration with French pharmaceutical firm Sanofi, according to a joint press release.

Blackstone will invest EUR 300m with the aim of getting Sanofi’s drug Sarclisa, a treatment of the type of bone marrow cancer known as multiple myeloma, on the market in a subcutaneous formulation, meaning the drug is administered under the skin.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs